Figure 1.

Clinicopathological Features of miR-3613-5p Expression

(A) The portion of the differentially expressed miRNAs in RELA-overexpressing A549 cells and its fold change. Red frame, miR-3613-5p. (B) Quantitative real-time PCR analysis of miR-3613-5p expression in A549 and H1299 cells after treatment with negative control (NC) or RELA plasmid, normalized to U6. Mean ± SD. ∗∗p < 0.01, ∗∗∗p < 0.001, by Student’s t test. (C) miR-3613-5p expression was detected by quantitative real-time PCR in normal lung samples and LUAD samples, normalized to U6. Mean ± SD. ∗∗∗p < 0.001, by Student’s t test. (D) miR-3613-5p expression in LUAD TMA. (a) Weak expression of miR-3613-5p in normal lung samples; (b) strong expression of miR-3613-5p in normal lung samples; (c) weak expression of miR-3613-5p in LUAD samples; and (d) strong expression of miR-3613-5p in LUAD samples (original magnification, ×200). Scale bars, 20 μm. (E) Kaplan-Meier survival analysis of overall survival of 92 LUAD patients based on miR-3613-5p expression. The log-rank test was used to calculate p values.